<PAGE>

EXHIBIT 99.1

ADVANCED BIOTHERAPY, INC. DISCLOSES USE PATENT FOR ANTIBODIES TO
INTERFERON-GAMMA IN THE TREATMENT OF FIVE AUTOIMMUNE DISEASES

WOODLAND HILLS, Calif.--(BW HealthWire)--Dec. 13, 2001--Advanced Biotherapy,
Inc. (OTCBB: ADVB - news) announced today that antibodies to interferon-gamma
(IFN-g) are now protected under U.S. patent law for use in five diseases of
autoimmune etiology. The announcement of the assignment of this patent number
coincides with the Company's annual stockholders meeting today.

The United States Patent and Trademark Office (USPTO) has assigned U.S. Patent
No. 6,333,032 to the Company for the exclusive use of IFN-g antibodies --
including humanized and fully human, as well as other antibody types -- to treat
Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Juvenile Rheumatoid
Arthritis, Psoriatic Arthritis (PA) and Ankylosing Spondylitis. The patent is
scheduled to issue and be available to the public on December 26, 2001.

Commenting on this announcement, Mr. Edmond Buccellato, President and Chief
Executive Officer, stated, "Advanced Biotherapy is now beginning to pursue
out-licensing agreements for the use of antibodies to IFN-g, and we believe that
this use patent issuance will add considerable value for prospective
collaborative partners. The patent provides a window of legal protection for
product development and protected commercialization for IFN-g antibody use as
monotherapy for these severe and often catastrophic autoimmune conditions, and
thus create significant opportunities, for any one of these diseases, to a
collaborative partner's product pipeline."

Alexander Cappello, Chairman of the Company's Board of Directors, stated, "In
light of accelerated developments and advances over the past several years in
antibody technology for the treatment of various autoimmune diseases, the
issuance of this patent heralds a significant milestone in the history of our
company and adds significant strength to our patent portfolio. We continue to
follow the progress of companies such as Abgenix, Inc. (NASDAQ: ABGX - news),
Protein Design Labs, Inc. (NASDAQ: PDLI - news), Medarex, Inc. (NASDAQ: MEDX -
news) and Cambridge Antibody Technology (NASDAQ: CATG - news), among others that
have developed and own technologies to manufacture humanized and fully human
antibodies that, in our view, validate the importance of this newly issued
patent."

According to the recent comprehensive biotechnology industry report,
"Therapeutic Monoclonal Antibody Industry Overview," published by emerging
growth investment bank Adams, Harkness & Hill, the market for antibody
technology is large, with projected continued growth. There were only ten FDA
approved monoclonal antibodies that collectively represented approximately $2.1
billion in sales during 2000, with projected sales of $2.7 billion during 2001.
The report forecasts 70 products, which are estimated to achieve annual global
sales of approximately $12.5 billion by the year 2008. The report emphasized
that the market for antibodies as biologically based drug products is diverse
enough to support multiple technologies protected by solid patent positions.

Dr. Simon Skurkovich, M.D., founder, former President, Chairman Emeritus and
Director of Research and Development for the Company, foresees Advance
Biotherapy's IFN-g antibodies as a significant portion of the antibody therapy
market growth. He stated, "The importance of IFN-g in the initiation and
prolongation of autoimmune disease is now well documented and understood in the
scientific community. The key role of IFN-g in the pathology of different
autoimmune diseases, together with the clinical data generated in our human
studies conducted in Russia, suggests that an anti-IFN-g therapeutic strategy
may be superior to existing therapies for both MS, RA, PA, and other autoimmune
diseases in both efficacy and safety." Reports of the Company's human studies
demonstrating proof-of-principle, and the beneficial effects of antibodies to
IFN-g in RA, Psoriatic Arthritis and MS were recently published in peer-reviewed
scientific journals.

Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the statements made,
including risks associated with the success of clinical trials, the progress of
research and product development programs, the regulatory approval process,
competitive products, future capital requirements and the extent and breadth of
the Company's patent portfolio. The foregoing discussion of the effect of the
patent issued involves risks and uncertainty, including the risks that third
parties may be successful in challenging the patent; or that granted claims may
be held invalid or interpreted differently by a court of law; or that new
technologies will be developed that are superior in treating the diseases
targeted by Advanced Biotherapy, Inc. See the Company's public filings with the
Securities and Exchange Commission for information about risks that may affect
the Company.


<PAGE>

--------------------
Contact:

     Advanced Biotherapy, Inc.
     Edmond Buccellato, 818/883-6716
     E-mail: ed@advancedbiotherapy.com
     Website: www.advancedbiotherapy.com





